Source comparison
Cycling versus continuous use
The FDA-approved protocol is continuous daily dosing. In the pooled Phase 3 program, tesamorelin was dosed every day for 52 continuous weeks: IGF-1 reached its elevated plateau by week 26 and was held at that level through week 52, and the trials documented no
This comparison does not assign a generated winner or score.
- The FDA-approved protocol is continuous daily dosing. In the pooled Phase 3 program, tesamorelin was dosed every day for 52 continuous weeks: IGF-1 reached its elevated plateau by week 26 and was held at that level through week 52, and the trials documented no tachyphylaxis (no loss of response over time) on continuous daily dosing, with visceral-fat reduction sustained across the full year (52-week extension, Falutz et al., 2010). Community off-label protocols often cycle 8-16 weeks on, 4-8 weeks off, typically described in the context of cost management and letting IGF-1 normalize between blocks. Use our tesamorelin cycle cost calculator to compare spending across different cycle lengths. Cycling means visceral fat may partially rebound during off periods, while continuous use mirrors the FDA-approved protocol and carries the strongest trial evidence for a sustained, non-attenuating response. See Do GH Peptides Desensitize the Pituitary? for how this compares across GH secretagogues.